BV+R-CHP
Phase 2Small molecule
BV+R-CHP is one of 8 small molecule programs targeting Brentuximab Vedotin. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Brentuximab Vedotin
#DrugCompanyPhaseTrials
1Adriamycin
PfizerPhase 3
Beyfortus
BeiGenePhase 3
DTIC-Dome
BayerPhase 3
Rayos
RRoxane Laboratories
Phase 3
Adcetris
PfizerPhase 2
Vepesid
AAvyxa
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
BV+R-CHP
TThe First Affiliated Hospital with Nanjing Medical University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Brentuximab Vedotin1 trial
Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06925555·25 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BV+R-CHP. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details